Plus therapeutics appoints dr. michael rosol as chief development officer

Austin, texas, feb. 20, 2025 (globe newswire) -- plus therapeutics, inc. (nasdaq: pstv) (the “company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (cns) cancers, today announced the appointment of michael rosol, ph.d., as chief development officer.
PSTV Ratings Summary
PSTV Quant Ranking